Form 4: Verona Pharma Director's Equity Changes Post-Merger

Verona Pharma director Lisa Deschamps reported changes in her beneficial ownership due to the company's acquisition by Merck Sharp & Dohme LLC.

Summary

• Lisa Deschamps, a Director of Verona Pharma plc, reported changes in her beneficial ownership of the company's securities on October 7, 2025.
• These transactions are a direct result of the acquisition of Verona Pharma plc by Merck Sharp & Dohme LLC and its wholly-owned subsidiary Vol Holdings LLC, through a Scheme of Arrangement under the UK Companies Act 2006.
• Ordinary Shares totaling 84,856 were disposed of directly as part of the Scheme of Arrangement.
• An additional 72,000 Ordinary Shares were acquired and subsequently disposed of directly, related to the conversion of Restricted Share Units (RSUs).
• All outstanding time-based Restricted Share Unit (RSU) awards, covering 72,000 underlying Ordinary Shares (equivalent to 9,000 ADSs), became fully vested immediately prior to the Effective Time and converted into a right to receive cash.
• All outstanding share options, totaling 600,000 underlying Ordinary Shares (equivalent to 75,000 ADSs) with various exercise prices, became fully vested immediately prior to the Effective Time and converted into a right to receive cash if their exercise price was less than the ADS Consideration.
• Each Scheme Share entitled holders to receive $13.375 in cash.
• Each American Depositary Share (ADS), representing eight Ordinary Shares, entitled holders to receive $107 in cash.

Sentiment

Score: 8

Explanation: The filing reports the successful execution of an acquisition, leading to a cash payout for shareholders and the vesting and conversion of equity awards for the director, which is a positive outcome for the involved stakeholders.

Positives

• The acquisition provides a clear cash exit for Verona Pharma plc shareholders at a fixed price of $13.375 per Ordinary Share or $107 per ADS.
• The reporting person's Restricted Share Units and share options fully vested and converted into cash, ensuring realization of their equity value.

Negatives

• Verona Pharma plc will cease to be an independent publicly traded entity following the completion of the acquisition.

Future Outlook

Verona Pharma plc is undergoing an acquisition by Merck Sharp & Dohme LLC, which will result in the company no longer being an independent publicly traded entity. All outstanding equity awards and shares are being converted into cash as per the terms of the Transaction Agreement.

Industry Context

The acquisition of Verona Pharma plc by Merck Sharp & Dohme LLC is consistent with ongoing consolidation trends within the pharmaceutical and biotechnology sectors, where larger companies often acquire smaller firms for their pipeline assets or market positions.

Stakeholder Impact

• Shareholders: Entitled to receive $13.375 in cash per Ordinary Share or $107 in cash per ADS.
• Equity Award Holders (e.g., Lisa Deschamps): Restricted Share Units and share options fully vested and converted into cash, providing a liquidity event for their equity holdings.
• Company: Verona Pharma plc will cease to exist as an independent publicly traded entity, becoming part of Merck Sharp & Dohme LLC.

Next Steps

• Finalization of the Scheme of Arrangement and integration of Verona Pharma plc into Merck Sharp & Dohme LLC.
• Delisting of Verona Pharma plc shares and ADSs from public exchanges.

Key Dates

Keywords

Verona Pharma, VRNA, SEC Form 4, Insider Transaction, Beneficial Ownership, Acquisition, Merger, Merck Sharp & Dohme, Scheme of Arrangement, Director, Equity Awards, Restricted Stock Units, Share Options